Phase 1 Data Shows a 43% Overall Response Rate at the Recommended Phase 2 Dose and Durable Responses Exceeding One Year and Ongoing, with a ...

A new paper was published in Oncoscience on June 28, 2023, entitled, "Adenoid cystic carcinoma of the head and neck—treatment strategies of a highly malignant tumor with variable localizations." In ...

Data for patients treated at or below recommended Phase 2 dose (RP2D) showed 84.6% disease control rate (33/39), including 3 partial responses (2 ...

Servier today announced that it will present new and updated data at the 2026 American Society of Clinical Oncology (ASCO) ...

Results of Phase 1 Dose-Escalation Cohort Including Antitumor Activity and Safety of REM-422 in Adenoid Cystic ...

BUFFALO, NY – December 4, 2024 – A new editorial was published in Oncotarget’s Volume 15 on November 22, 2024, entitled “B7-H4: A potential therapeutic target in adenoid cystic carcinoma.” Researchers ...

A paper published by researchers at Fox Chase Cancer Center highlights the case of a patient who was diagnosed with adenoid cystic carcinoma (ACC) after a molecular panel identified the presence of an ...

Adenoid cystic carcinoma (ACC) of the breast is a rare and distinctive form of breast cancer, accounting for less than 0.1% of all breast malignancies. Despite its triple‐negative immunophenotype, ...

The malignancies of Bartholin's gland, although exceedingly rare, represent a diagnostic and therapeutic challenge for clinicians. Bartholin’s gland carcinoma encompasses several histological subtypes ...

A new editorial paper was published in Oncoscience (Volume 10) on June 28, 2023, entitled, "Adenoid cystic carcinoma of the head and neck – treatment strategies of a highly malignant tumor with ...

REM-422 is the first oral mRNA degrader of MYB demonstrating proof-of-concept in ACC. In this study, pharmacokinetic and pharmacodynamic analyses conirmed robust compound exposure in blood and target ...